Posterior Tibial Nerve Stimulation for Overactive Bladder: Mechanism, Classification, and Management Outlines

• Published in: Parkinson's disease Vol. 2022; pp. 2700227 - 12
• Main Authors: Al-Danakh, Abdullah, Safi, Mohammed, Alradhi, Mohammed, Almoiliqy, Marwan, Chen, Qiwei, Al-Nusaif, Murad, Yang, Xuehan, Al-Dherasi, Aisha, Zhu, Xinqing, Yang, Deyong
• Format: Journal Article
• Language: English
• Published: United States Hindawi 16.03.2022; Hindawi Limited; Wiley
• Subjects: 18th century; 19th century; Acupuncture; Analysis; Bladder; Clinical trials; COVID-19; FDA approval; Fecal incontinence; Neurophysiology; Patients; Pelvis; Review; Sacrum; Spinal cord; Tibial nerve; Urinary incontinence; Urination; Urogenital system; Urology; China; United States > US
• ISSN: 2090-8083; 2042-0080
• DOI: 10.1155/2022/2700227

Purpose of the Review. Posterior tibial nerve stimulation (PTNS) techniques have dramatically grown after approval to manage overactive bladder (OAB). The present review will focus on the most current data on PTNS types (percutaneous, transcutaneous, and implant) and their mechanism of action, safety, efficacy, advantages, drawbacks, limitation, and clinical applications. Recent Findings. The present review described the recent studies that addressed the tibial nerve stimulation role in OAB management. BlueWind RENOVA system, Bioness StimRouter, and eCoin are examples of emerging technologies that have evolved from interval sessions (percutaneous PTNS and transcutaneous PTNS) to continuous stimulation (implants). These can be efficiently managed at home by patients with minimum burden on the health system and fewer visits, especially in the COVID-19 pandemic. Summary. Our review shows that the tibial nerve stimulation advancements in OAB treatment have been rapidly increasing over the recent years. It is minimally invasive and effective, similar to sacral nerve stimulation (SNM), but less aggressive. Implantable PTNS has been promised in terms of efficacy, safety, and high acceptance rate. However, evidence is still limited to short-term trials, and tolerability, method, and drawbacks remain challenges.